FDA Biomarker Program Needs Overhaul, Genentech Says
Executive Summary
Outside experts could provide 'consultation and advice' to sponsors developing qualification plans and to FDA in evaluating qualification submissions.
You may also be interested in...
Blame The Science, Not Regulation, For Targeted Therapy Shortfalls – FDA
In a report both boastful and defensive in tone, the agency explains why some disease areas are rife with targeted therapies while others have few or none.
Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?
FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.